Trastuzumab deruxtecan
About
Therapy type: Targeted therapy
Therapy strategy: HER2 inhibition
Mappings
NCI Thesaurus: Trastuzumab Deruxtecan (ncit:C128799)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab deruxtecan | FDA |
| Sensitivity (+) | HER2-low | Invasive Breast Carcinoma | Trastuzumab deruxtecan | FDA |
| Sensitivity (+) | ERBB2 oncogenic variants | Non-Small Cell Lung Cancer | Trastuzumab deruxtecan | FDA |
| Sensitivity (+) | HER2-positive | Adenocarcinoma of the Gastroesophageal Junction | Trastuzumab deruxtecan | FDA |
| Sensitivity (+) | HER2-positive | Any solid tumor | Trastuzumab deruxtecan | FDA |
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Pertuzumab, Trastuzumab deruxtecan | FDA |
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab deruxtecan | HC |
| Sensitivity (+) | HER2-low | Invasive Breast Carcinoma | Trastuzumab deruxtecan | HC |
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab deruxtecan | HC |
| Sensitivity (+) | HER2-positive | Adenocarcinoma of the Gastroesophageal Junction | Trastuzumab deruxtecan | HC |